A grade 3 ER-positive HER2-negative phenotype occurred in 15/43 (34.9%) PALB2 PGVs, while accounting for 254/1843 (13.8%) breast cancers (OR = 3.35, 95% CI = 1.76-6.44, P = 0.0005). Here, PALB2 is linked to breast cancer.